PLYMOUTH
MEETING, Pa., Oct. 30,
2024 /PRNewswire/ -- Harmony Biosciences Holdings,
Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of
the previously announced underwritten public offering of an
aggregate of 8,000,000 shares of the Company's common stock, par
value $0.00001 per share ("Common
Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings,
LLC (together, the "Selling Shareholders") at a public offering
price of $31.00 per share. The
Selling Shareholders have granted the underwriter a 30-day option
to purchase an additional 1,200,000 shares of Common Stock from the
Selling Shareholders at the public offering price, less
underwriting discounts and commissions. The Company is not offering
any shares of Common Stock in the offering and will not receive any
proceeds from the sale of shares in the offering. The offering is
expected to close on November 1,
2024, subject to customary closing conditions.
J.P. Morgan is acting as the sole book-running manager for the
offering.
The shares of Common Stock are being offered and will be sold
pursuant to an effective shelf registration statement that was
previously filed with the SEC and became effective automatically
upon filing. The offering of these securities is being made only by
means of a prospectus supplement and accompanying base prospectus,
as filed with the Securities and Exchange Commission (the "SEC").
The preliminary prospectus supplement and accompanying base
prospectus relating to the offering was filed with the SEC and may
be obtained free of charge on the SEC's website at www.sec.gov
under the Company's name. When available, copies of the final
prospectus supplement and accompanying base prospectus relating to
the offering may be obtained free of charge on the SEC's website at
www.sec.gov under the Company's name or from J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by
telephone at (866) 803-9204, or by emailing
prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About the Company
The Company is a pharmaceutical company dedicated to developing
and commercializing innovative therapies for patients with rare
neurological diseases who have unmet medical needs. Driven by novel
science, visionary thinking, and a commitment to those who feel
overlooked, the Company is nurturing a future full of therapeutic
possibilities that may enable patients with rare neurological
diseases to truly thrive. Established by Paragon Biosciences, LLC,
in 2017 and headquartered in Plymouth
Meeting, Pa, we believe that when empathy and innovation
meet, a better future can begin; a vision evident in the
therapeutic innovations we advance, the culture we cultivate, and
the community programs we foster.
Forward Looking Statements
This press release contains "forward-looking statements"
within the meaning of U.S. federal securities laws. Words such as
"anticipate," "estimate," "expect," "forecast," "guidance,"
"could," "may," "should," "would," "believe," "intend," "project,"
"plan," "predict," "will," "target" and similar expressions
identify forward-looking statements, which are not historical in
nature. These forward-looking statements include, but are not
limited to, statements regarding the consummation of the offering.
Forward-looking statements are subject to certain known and unknown
risks and uncertainties that could cause actual results to differ
materially from our historical experience and our current
projections or expectations of future results expressed or implied
by these forward-looking statements. You should keep in mind the
risk factors and other cautionary statements in the filings made by
the Company with the SEC, which are available to the public. The
Company undertakes no obligation to, and does not intend to, update
these forward-looking statements to reflect events or circumstances
occurring after this press release. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release.
View original
content:https://www.prnewswire.com/news-releases/harmony-biosciences-holdings-inc-announces-pricing-of-public-offering-of-common-stock-by-selling-shareholders-302292279.html
SOURCE Harmony Biosciences